MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Pacira Pharmaceuticals Inc-DE

Suletud

SektorTervishoid

25.98 3.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.96

Max

26

Põhinäitajad

By Trading Economics

Sissetulek

160M

16M

Müük

19M

187M

P/E

Sektori keskmine

11.23

57.333

Aktsiakasum

0.91

Kasumimarginaal

8.566

Töötajad

788

EBITDA

165M

51M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+36.07% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-26M

1.2B

Eelmine avamishind

22.8

Eelmine sulgemishind

25.98

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Pacira Pharmaceuticals Inc-DE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2025, 23:45 UTC

Kuumad aktsiad

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2. juuli 2024, 16:22 UTC

Suurimad hinnamuutused turgudel

Pacira BioSciences Shares Tumble as FDA Approves Exparel Generic

Võrdlus sarnastega

Hinnamuutus

Pacira Pharmaceuticals Inc-DE Prognoos

Hinnasiht

By TipRanks

36.07% tõus

12 kuu keskmine prognoos

Keskmine 34.29 USD  36.07%

Kõrge 65 USD

Madal 21 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Pacira Pharmaceuticals Inc-DE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

3

Osta

4

Hoia

1

Müü

Tehniline skoor

By Trading Central

25.135 / 25.84Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.